
Please try another search
After-Hours Stock Movers:
Amazon.com (NASDAQ:AMZN) 14% LOWER; reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $127.1 billion versus the consensus estimate of $127.76 billion. Amazon sees Q4 2022 revenue of $140 billion-148 billion, versus the consensus of $155.1 billion.
Edwards Lifesciences (NYSE:EW) 11% LOWER; reported Q3 EPS of $0.61, $0.01 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.33 billion. Edwards Lifesciences sees FY2022 EPS of $2.40-$2.50, versus the consensus of $2.52.
Pinterest (NYSE:PINS) 10% HIGHER; reported Q3 EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $685 million versus the consensus estimate of $665.54 million.
L3Harris Technologies (NYSE:LHX) 8% LOWER; reported Q3 EPS of $3.26, $0.15 worse than the analyst estimate of $3.41. Revenue for the quarter came in at $4.25 billion versus the consensus estimate of $4.41 billion. L3Harris Technologies sees FY2022 EPS of $12.75-$13.00, versus the consensus of $13.48. L3Harris Technologies sees FY2022 revenue of $16.8 million, versus the consensus of $17.39 million.
DexCom (NASDAQ:DXCM) 7% HIGHER; reported Q3 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the quarter came in at $769.6 million versus the consensus estimate of $751.74 million. DexCom sees Q4 2022 revenue of $2.88 billion-2.91 billion, versus the consensus of $2.89 billion.
Deckers Brands (NYSE:DECK) 6% LOWER; reported Q2 EPS of $3.80, $0.17 better than the analyst estimate of $3.63. Revenue for the quarter came in at $876 million versus the consensus estimate of $804.64 million. Deckers Brands sees FY2023 EPS of $17.50-$18.35, versus the consensus of $18.12.
Vertex Pharma (NASDAQ:VRTX) 5% HIGHER; reported Q3 EPS of $4.01, $0.39 better than the analyst estimate of $3.62. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.22 billion. Vertex Pharma sees FY2022 revenue of $8.8 billion-8.9 billion, versus the prior of $8.6 billion-$8.8 billion and the consensus of $8.77 billion.
Gilead Sciences (NASDAQ:GILD) 4% HIGHER; reported Q3 EPS of $1.90, $0.38 better than the analyst estimate of $1.52. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.13 billion.
Intel (NASDAQ:INTC) 4% HIGHER; reported Q3 EPS of $0.59, $0.25 better than the analyst estimate of $0.34. Revenue for the quarter came in at $15.3 billion versus the consensus estimate of $15.43 billion. Intel sees Q4 2022 EPS of $0.20, versus the consensus of $0.60. Intel sees Q4 2022 revenue of $14 billion-15 billion, versus the consensus of $16.3 billion
T-Mobile (NASDAQ:TMUS) 3% HIGHER; reported Q3 EPS of $0.40, $0.01 better than the analyst estimate of $0.39. Revenue for the quarter came in at $19.48 billion versus the consensus estimate of $20.02 billion.
Apple Inc (NASDAQ:AAPL) 1% LOWER; reported Q4 EPS of $1.29, $0.03 better than the analyst estimate of $1.26. Revenue for the quarter came in at $90.1 billion versus the consensus estimate of $88.76 billion.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.